Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones

Molecular Metabolism

Volumn 2, Issue 3, 2013, Pages 205-214

  Adams, Andrew C ^a   Coskun, Tamer ^a   Cheng, Christine C ^a   O'Farrell, Libbey S ^a   DuBois, Susan L ^a   Kharitonenkov, Alexei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adiponectin; FGF21; Metabolism; PPAR ; Rosiglitazone

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 21; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BIOACCUMULATION; BODY COMPOSITION; BODY MASS; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; GENOTYPE; GLYCEMIC CONTROL; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUMOYLATION; UPREGULATION;

ANIMALIA; MUS;

EID: 84883260199     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.05.005     Document Type: Article

References (46)

1. Adams A.C., Cheng C.C., Coskun T., Kharitonenkov A. FGF21 requires betaklotho to act in vivo. PloS One 2012, 7:e49977.
2. Adams A.C., Coskun T., Irizarry Rovira A.R., Schneider M.A., Raches D.W., Micanovic R., Bina H.A., Dunbar J.D., Kharitonenkov A. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012, 7:e38438.
3. Adams A.C., Kharitonenkov A. FGF21: the center of a transcriptional nexus in metabolic regulation. Current Diabetes Reviews 2012, 8:285-293.
4. Adams A.C., Yang C., Coskun T., Cheng C.C., Gimeno R.E., Luo Y., Kharitonenkov A. The breadth of FGF21s metabolic actions are governed by FGFR1 in adipose tissue. Molecular Metabolism 2013, 2:31-37.
5. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
6. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007, 5:426-437.
7. Chartoumpekis D.V., Habeos I.G., Ziros P.G., Psyrogiannis A.I., Kyriazopoulou V.E., Papavassiliou A.G. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Molecular Medicine 2011, 17:736-740.
8. Christodoulides C., Dyson P., Sprecher D., Tsintzas K., Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. Journal of Clinical Endocrinology and Metabolism 2009, 94:3594-3601.
9. Coskun T., Bina H.A, Schneider M.A., Dunbar J.D., Hu C.C. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
10. Ding X., Boney-Montoya J., Owen B.M., Bookout A.L., Coate K.C., Mangelsdorf D.J., Kliewer S.A. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metabolism 2012, 16:387-393.
11. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., Badman M.K., Martinez-Chantar M.L., Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
12. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
13. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., Maratos-Flier E. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
14. Fisher F.M., Estall J.L., Adams A.C., Antonellis P.J., Bina H.A., Flier J.S., Kharitonenkov A., Spiegelman B.M., Maratos-Flier E. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011, 152:2996-3004.
15. Fisher F.M., Kleiner S., Douris N., Fox E.C., Mepani R.J., Verdeguer F., Wu J., Kharitonenkov A., Flier J.S., Maratos-Flier E., et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes & Development 2012, 26:271-281.
16. Galman C., Lundasen T., Kharitonenkov A., Bina H.A., Eriksson M., Hafstrom I., Dahlin M., Amark P., Angelin B., Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism 2008, 8:169-174.
17. Hale C., Chen M.M., Stanislaus S., Chinookoswong N., Hager T., Wang M., Veniant M.M., Xu J. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 2012, 153:69-80.
18. Holland W.L., Adams A.C., Brozinick J.T., Bui H.H., Miyauchi Y., Kusminski C.M., Bauer S.M., Wade M., Singhal E., Cheng C.C., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metabolism 2013, 17:790-797.
19. Hondares E., Rosell M., Gonzalez F.J., Giralt M., Iglesias R., Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metabolism 2010, 11:206-212.
20. Hotta Y., Nakamura H., Konishi M., Murata Y., Takagi H., Matsumura S., Inoue K., Fushiki T., Itoh N. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009, 150:4625-4633.
21. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 2007, 5:415-425.
22. Kharitonenkov A., Dunbar J.D., Bina H.A., Bright S., Moyers J.S., Zhang C., Ding L., Micanovic R., Mehrbod S.F., Knierman M.D., et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Journal of Cellular Physiology 2008, 215:1-7.
23. Kharitonenkov A., Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends in Endocrinology and Metabolism 2011, 22:81-86.
24. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., et al. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005, 115:1627-1635.
25. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., Hansen B.C., Shanafelt A.B., Etgen G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
26. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. Journal of Biological Chemistry 2007, 282:26687-26695.
27. Kusminski C.M., Scherer P.E. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clinical Pharmacology and Therapeutics 2009, 86:592-595.
28. Li K., Li L., Yang M., Zong H., Liu H., Yang G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. European Journal of Endocrinology/European Federation of Endocrine Societies 2009, 161:391-395.
29. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., Itoh N., Wang Y., Bornstein S.R., Xu A., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metabolism 2013, 17:779-789.
30. Liu H.H., Lu P., Guo Y., Farrell E., Zhang X., Zheng M., Bosano B., Zhang Z., Allard J., Liao G., et al. An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen-induced liver toxicity. Genome Research 2010, 20:28-35.
31. Lundasen T., Hunt M.C., Nilsson L.M., Sanyal S., Angelin B., Alexson S.E., Rudling M. PPARalpha is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 2007, 360:437-440.
32. Moyers J.S., Shiyanova T.L., Mehrbod F., Dunbar J.D., Noblitt T.W., Otto K.A., Reifel-Miller A., Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. Journal of Cellular Physiology 2007, 210:1-6.
33. Mu J., Pinkstaff J., Li Z., Skidmore L., Li N., Myler H., Dallas-Yang Q., Putnam A.M., Yao J., Bussell S., et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012, 61:505-512.
34. Muise E.S., Azzolina B., Kuo D.W., El-Sherbeini M., Tan Y., Yuan X., Mu J., Thompson J.R., Berger J.P., Wong K.K. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Molecular Pharmacology 2008, 74:403-412.
35. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimica et Biophysica Acta 2000, 1492:203-206.
36. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K.P., Goetz R., Eliseenkova A.V., Mohammadi M., Kuro-o M. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:7432-7437.
37. Ohshima T., Koga H., Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. Journal of Biological Chemistry 2004, 279:29551-29557.
38. Oishi K., Tomita T. Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biological & Pharmaceutical Bulletin 2011, 34:1120-1121.
39. Oishi K., Uchida D., Ishida N. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver. FEBS Letters 2008, 582:3639-3642.
40. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
41. Suzuki M., Uehara Y., Motomura-Matsuzaka K., Oki J., Koyama Y., Kimura M., Asada M., Komi-Kuramochi A., Oka S., Imamura T. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Molecular Endocrinology 2008, 22:1006-1014.
42. Veniant M.M., Hale C., Helmering J., Chen M.M., Stanislaus S., Busby J., Vonderfecht S., Xu J., Lloyd D.J. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 2012, 7:e40164.
43. Wang H., Qiang L., Farmer S.R. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Molecular and Cellular Biology 2008, 28:188-200.
44. Wang Z.J., Liu Q., Li P.P., Zou C.H., Shen Z.F. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. European Journal of Pharmacology 2008, 580:277-283.
45. Yang C., Jin C., Li X., Wang F., McKeehan W.L., Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 2012, 7:e33870.
46. Zhang Y., Xie Y., Berglund E.D., Coate K.C., He T.T., Katafuchi T., Xiao G., Potthoff M.J., Wei W., Wan Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 2012, 1:e00065.